CA3095012C - Methods for treating and diagnosing blinding eye diseases - Google Patents

Methods for treating and diagnosing blinding eye diseases Download PDF

Info

Publication number
CA3095012C
CA3095012C CA3095012A CA3095012A CA3095012C CA 3095012 C CA3095012 C CA 3095012C CA 3095012 A CA3095012 A CA 3095012A CA 3095012 A CA3095012 A CA 3095012A CA 3095012 C CA3095012 C CA 3095012C
Authority
CA
Canada
Prior art keywords
faf
rpe
eye
subject
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3095012A
Other languages
English (en)
French (fr)
Other versions
CA3095012A1 (en
Inventor
Shelley Romayne BOYD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translatum Medicus Inc
Original Assignee
Translatum Medicus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translatum Medicus Inc filed Critical Translatum Medicus Inc
Publication of CA3095012A1 publication Critical patent/CA3095012A1/en
Application granted granted Critical
Publication of CA3095012C publication Critical patent/CA3095012C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3095012A 2012-05-01 2013-04-30 Methods for treating and diagnosing blinding eye diseases Active CA3095012C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261640854P 2012-05-01 2012-05-01
US61/640,854 2012-05-01
US201261641393P 2012-05-02 2012-05-02
US61/641,393 2012-05-02
US201261693226P 2012-08-24 2012-08-24
US61/693,226 2012-08-24
US201361792436P 2013-03-15 2013-03-15
US61/792,436 2013-03-15
CA2911041A CA2911041C (en) 2012-05-01 2013-04-30 Methods for treating and diagnosing blinding eye diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2911041A Division CA2911041C (en) 2012-05-01 2013-04-30 Methods for treating and diagnosing blinding eye diseases

Publications (2)

Publication Number Publication Date
CA3095012A1 CA3095012A1 (en) 2013-11-07
CA3095012C true CA3095012C (en) 2023-02-07

Family

ID=49514154

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3095012A Active CA3095012C (en) 2012-05-01 2013-04-30 Methods for treating and diagnosing blinding eye diseases
CA2911041A Active CA2911041C (en) 2012-05-01 2013-04-30 Methods for treating and diagnosing blinding eye diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2911041A Active CA2911041C (en) 2012-05-01 2013-04-30 Methods for treating and diagnosing blinding eye diseases

Country Status (9)

Country Link
EP (2) EP2844250B1 (https=)
JP (3) JP2015523546A (https=)
CN (2) CN104334173B (https=)
AU (2) AU2013255050B2 (https=)
CA (2) CA3095012C (https=)
DK (1) DK2844250T3 (https=)
ES (1) ES2656292T3 (https=)
IL (3) IL235395A (https=)
WO (1) WO2013163758A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
ES2789849T3 (es) * 2014-05-15 2020-10-26 Translatum Medicus Inc Composiciones y procedimientos para el tratamiento y diagnóstico de trastornos oculares
CA2989270A1 (en) * 2015-06-16 2016-12-22 Translatum Medicus, Inc. Compositions and methods for treating and diagnosing ocular disorders
JP6664115B2 (ja) * 2016-03-15 2020-03-13 原　英彰 アフリベルセプトによる網膜保護作用
CN109788946B (zh) * 2016-06-24 2023-02-03 鲁美斯Be有限公司 利用激光等效强脉冲光装置的选择性皮肤处理
EP3525659A4 (en) 2016-10-13 2020-06-17 Translatum Medicus, Inc. SYSTEMS AND METHODS FOR DETECTING EYE DISEASES
CN110213987A (zh) * 2016-12-05 2019-09-06 杰克逊实验室 视网膜和视神经中的脂肪滴作为人类的神经变性和青光眼的诊断标志物
US20210060017A1 (en) * 2018-02-27 2021-03-04 Shilpa Medicare Ltd Methotrexate ophthalmic solution
CN111970957B (zh) * 2018-04-18 2024-02-27 株式会社尼康 图像处理方法、计算机可读的存储介质及图像处理装置
CN118505665A (zh) * 2018-04-18 2024-08-16 株式会社尼康 图像处理方法、图像处理装置、存储介质及眼科系统
CN109222890A (zh) * 2018-08-24 2019-01-18 微云（武汉）科技有限公司 一种眼睛健康情况确定方法、装置和存储介质
CN109585017B (zh) * 2019-01-31 2023-12-12 上海宝藤生物医药科技股份有限公司 一种年龄相关性黄斑变性的风险预测算法模型和装置
WO2020261158A1 (en) 2019-06-25 2020-12-30 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
AU2021225926A1 (en) 2020-02-26 2022-10-20 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
JP7406403B2 (ja) 2020-02-28 2023-12-27 浜松ホトニクス株式会社 眼底画像処理方法、眼底画像処理装置、眼底画像処理プログラム、及びそのプログラムを記録する記録媒体
CN114099515A (zh) * 2021-12-27 2022-03-01 中山大学中山眼科中心 氨甲蝶呤在制备治疗视网膜色素变性的药物方面的应用
WO2024165925A1 (en) * 2023-02-10 2024-08-15 Translatum Medicus Inc. Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DK0770397T3 (da) 1995-10-18 2004-08-09 Akzo Nobel Nv Newcastle disease viruskombinationsvaccine
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
MXPA01013199A (es) 1999-06-30 2003-08-20 Tularik Inc Compuestos para la modulacion de la actividad de ppary.
WO2001064749A2 (en) 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
JP4764590B2 (ja) * 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
WO2002068386A2 (en) 2001-02-27 2002-09-06 The Johns Hopkins University Tools and methods for identifying ppar$g(d)-specific agonists and antagonists
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
EP1511736A4 (en) 2002-06-07 2006-06-07 Cortical Pty Ltd THERAPEUTIC MOLECULES AND METHOD 1
AU2003215549A1 (en) 2003-02-03 2004-08-30 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
WO2006012135A1 (en) 2004-06-24 2006-02-02 Janssen Pharmaceutica, N. V. Quaternary salt ccr2 antagonists
CN101065374A (zh) 2004-09-28 2007-10-31 詹森药业有限公司 取代的二哌啶化学引诱物细胞因子受体2拮抗剂
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
CN101410107A (zh) 2005-12-21 2009-04-15 科蒂科股份有限公司 Mif抑制剂
WO2007130712A1 (en) 2006-01-31 2007-11-15 Janssen Pharmaceutica, Nv Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases
DE102006030382A1 (de) * 2006-06-29 2008-01-03 Carl Zeiss Meditec Ag Verfahren und Vorrichtung zur optischen Detektion am Auge
WO2009109613A2 (en) * 2008-03-07 2009-09-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
NZ588033A (en) 2008-03-20 2012-11-30 Carolus Therapeutics Inc Methods of treating a mif-mediated disorder
WO2010129843A1 (en) * 2009-05-08 2010-11-11 Cytopathfinder, Inc. Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
TW201202214A (en) * 2010-05-27 2012-01-16 Santen Pharmaceutical Co Ltd Novel indazole derivative or salt thereof, production intermediate thereof, and prophylactic or therapeutic agent for chorioretinal degeneratire disease using the same
JP2012006918A (ja) * 2010-05-27 2012-01-12 Santen Pharmaceut Co Ltd イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤
EP2593117B1 (en) * 2010-07-12 2019-03-20 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same

Also Published As

Publication number Publication date
IL254995B (en) 2018-08-30
CN104334173B (zh) 2017-05-03
IL254995A0 (en) 2017-12-31
JP2019194230A (ja) 2019-11-07
JP6837522B2 (ja) 2021-03-03
CN107050020A (zh) 2017-08-18
JP2015523546A (ja) 2015-08-13
WO2013163758A1 (en) 2013-11-07
ES2656292T3 (es) 2018-02-26
CA2911041A1 (en) 2013-11-07
AU2016219703B2 (en) 2017-09-14
DK2844250T3 (en) 2018-01-08
EP2844250B1 (en) 2017-11-08
AU2013255050A1 (en) 2014-11-13
CA2911041C (en) 2020-12-15
JP2017114894A (ja) 2017-06-29
CN104334173A (zh) 2015-02-04
AU2016219703A1 (en) 2016-09-15
AU2013255050B2 (en) 2016-07-28
IL235395A (en) 2017-10-31
EP2844250A4 (en) 2015-11-18
EP3338776A1 (en) 2018-06-27
EP2844250A1 (en) 2015-03-11
IL260714B (en) 2019-08-29
CA3095012A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
US12377171B2 (en) Methods for treating and diagnosing blinding eye diseases
AU2016219703B2 (en) Methods for treating and diagnosing blinding eye diseases
US20180338952A1 (en) Compositions and methods for treating and diagnosing ocular disorders
CA2870353C (en) Compositions and methods for treating and diagnosing ocular disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201208

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250422

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260420

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260420